Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Merck & Company Inc (MRK)

NYSE
Currency in USD
Disclaimer
125.21
-0.16(-0.13%)
Closed
After Hours
125.32+0.11(+0.09%)

MRK Comments

MRK continues its 12-year dividend growth track record with the recent 6% dividend bump to $0.69
already +6% in Europe (premarket)
it was strange to watch the +6% premarket fall back to <1% before US market open and than back.
The stock price should be exceed 90 in very few days…
The drug, molnupiravir, could provide a much-needed weapon against the virus as colder weather pushes case counts higher and U.S. officials brace for the arrival of the new omicron variant.
ı wanna ask a question there iş a news about dividend. it is mention about $0.69. Does that mean we're going to get $0.69 per share?
Yes
thank you
Approve Approve Approve. Hopefully stock price reflect it soon!!
FDA advisory panel narrowly endorses Merck's oral Covid treatment pill, despite reduced efficacy and safety questionshttps://www.cnbc.com/2021/11/30/fda-advisory-panel-narrowly-endorses-mercks-oral-covid-treatment-pill-despite-reduced-efficacy.html?__source=androidappshare
Any news of the FDA approval of molnupiravir yet?
Approval 🚀🚀🚀🚀🚀🚀hopefullyyyy
Still debating yet #ApproveMerck
it is also said to be effective against all variants
US experts are now evaluating the anti-COVID-19 pill Merck. If recommended, our patience will have paid off!
will buy some more today if it goes down 1-2$ more :)
same
🚀🚀🚀🚀🚀🚀🚀Approveful of Anti-Virus Pill today hooefully
Bought some more for 74,35$
probably some hidden news like the pill is not good
why is this falling?
It was falling becuase FDA is meeting well now today on Covid drug. Pharma will always do that ahead of FDA panel or wether or hot gets approved. What i been hearing out of FDA and article is most likely.
do u think FDA will approve covid drug pill with 30% effective instead of 50% as original announcemnet???
bought some today $75.81 long
very good
An anti viral that deals with any covid variant that comes ….market selling off because of a variant
The pill showed meaningful result
Serbia to get first doses of Merck's COVID-19 drug in Dec - health official
EU watchdog could approve Merck Covid pill 'within weeks'
bad stock
Merck announces completion of Acceleron Pharma acquisition
Next month will be a good month
euro approves it still no demand lol
time will tell on the next earnings report
How is it possible that the stock does not rise further to the news of the pill approval in the EU
...
...
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.